APA (7th ed.) Citation

JM, S., JM, G., JA, H., B, H., H, M., MS, N., . . . N, M. (2024). Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance. Antimicrobial agents and chemotherapy, 68(1), e0095323. https://doi.org/10.1128/aac.00953-23

Chicago Style (17th ed.) Citation

JM, Strizki, et al. "Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants and Exhibits a High Barrier to the Development of Resistance." Antimicrobial Agents and Chemotherapy 68, no. 1 (2024): e0095323. https://doi.org/10.1128/aac.00953-23.

MLA (9th ed.) Citation

JM, Strizki, et al. "Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants and Exhibits a High Barrier to the Development of Resistance." Antimicrobial Agents and Chemotherapy, vol. 68, no. 1, 2024, p. e0095323, https://doi.org/10.1128/aac.00953-23.